IP Library Patent Application 14950387
Patent Application
App. No. 14/950,387

PRODUCTS AND METHODS FOR DELIVERY OF POLYNUCLEOTIDES BY ADENO-ASSOCIATED VIRUS FOR LYSOSOMAL STORAGE DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/950,387
Abstract

The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA.

Claims (10)

1 - 16 . (canceled)

17 . A method of delivering an N-sulphoglucosamine sulphohydrolase polynucleotide to a patient comprising the step of systemically administering a rAAV9 or rh74 comprising a self-complementary genome including the polynucleotide to a patient.

18 .- 26 . (canceled)

27 . A method of treating mucopolysaccharidosis IIIA comprising the step of systemically administering a rAAV9 or rh74 comprising a self-complementary genome including an N-sulphoglucosamine sulphohydrolase polynucleotide to a patient.

28 . The method of claim 17 or 27 wherein mannitol is administered prior to the administration of the rAAV.

29 . The method of any one of claim 17 , 27 or 28 wherein the sequence of the N-sulphoglucosamine sulphohydrolase polynucleotide is set out in SEQ ID NO: 3.

30 . A rAAV9 or rh74 comprising a genome encoding N-sulphoglucosamine sulphohydrolase.

31 . A composition comprising the rAAV9 or rh74 of claim 30 .

32 . The rAAV9 or rh74 of claim 30 wherein the sequence of the N-sulphoglucosamine sulphohydrolase polynucleotide is set out in SEQ ID NO: 3.

33 . The composition of claim 31 wherein the sequence of the N-sulphoglucosamine sulphohydrolase polynucleotide is set out in SEQ ID NO: 3.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2016
From: MCCARTY, DOUGLAS M.; FU, HAIYAN
To: NATIONWIDE CHILDREN'S HOSPITAL, INC.
Reel/Frame 040804/0889 →